Month: February 2022

Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine * Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus) * In the VAT08 Phase 3 primary series trial, two doses of the Sanofi-GSK vaccine in seronegative populations demonstrated:* 100% efficacy against severe COVID-19 disease and hospitalizations * 75% efficacy against moderate or severe COVID-19 disease* 57.9% efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern * Favorable safety profile following both primary series and booster vaccinations Paris, February 23, 2022. Sanofi and GSK today announce that they intend to submit data from both their booster and Phase...

Flywire integrates directly into the Adapt IT student management system to digitize and streamline cross-border education payments into South Africa BOSTON and JOHANNESBURG, South Africa, Feb. 23, 2022 (GLOBE NEWSWIRE) — Today, Flywire Corporation (Flywire) (Nasdaq: FLYW) a global payments enablement and software company announced the availability of an integration with Adapt IT Education, a division of Adapt IT Holdings Limited to streamline and digitize cross-border education payments for students studying in South Africa. As the exclusive international payments partner for Adapt IT, Flywire will improve the payment experience for students and their families, and the institutions that use Adapt IT software. A direct integration with Adapt IT’s ITS Integrator student management system improves operational efficiencies and...

Sanofi and GSK to seek regulatory authorization for COVID-19 vaccine * Final analysis of the global VAT02 booster trial confirms universal ability to boost neutralizing antibodies 18- to 30-fold across vaccine platforms (mRNA, adenovirus) * In the VAT08 Phase 3 primary series trial, two doses of the Sanofi-GSK vaccine in seronegative populations demonstrated:* 100% efficacy against severe COVID-19 disease and hospitalizations * 75% efficacy against moderate or severe COVID-19 disease* 57.9% efficacy against any symptomatic COVID-19 disease, in line with expected vaccine effectiveness in today’s environment dominated by variants of concern * Favorable safety profile following both primary series and booster vaccinations Paris, February 23, 2022. Sanofi and GSK today announce that they intend to submit data from both their booster and Phase...

Nasdaq Copenhagen                                                                                Nikolaj Plads 6 DK-1067 Copenhagen K    Copenhagen, 23 February 2022 ANNOUNCEMENT no. 1/2022 FINANCIAL CALENDAR 2022/2023 The financial calendar for 2022/2023 has been scheduled as follows: 2022:                           23.02.2022                    Annual Report 2021 24.03.2022                    Annual General Meeting 31.08.2022                    Interim Report, H1 2023: 22.02.2023                    Annual Report 2022 23.03.2023                    Annual General Meeting Cemat A/S Frede ClausenChairman of the Board This announcement has been prepared in a Danish-language and an English-language version. In case of doubt, the Danish version prevails.AttachmentAnnouncement (UK) no. 1 – 23.02.2022 –...

The center expands Synaptics’ European presence and leverages a strong base of local analog and RF expertise to advance the state-of-the-art in Wi-Fi and Bluetooth connectivity for the IoT.Synaptics Opens Wireless Research and Development Center in France New wireless R&D center in Sophia Antipolis expands Synaptics’ European presence and leverages a strong base of local analog and RF expertise to advance the state-of-the-art in Wi-Fi and Bluetooth connectivity for the IoT.SAN JOSE, Calif., Feb. 23, 2022 (GLOBE NEWSWIRE) — Synaptics® Incorporated (Nasdaq: SYNA) today announced the opening of a wireless research and development center in the Sophia Antipolis technology park in southeast France. Focused on Wi-Fi® and Bluetooth® hardware and software development, the facility will serve as a hub for the design of Synaptics’...

FLSmidth has received the enclosed notification pursuant to Article 19 of EU Regulation no. 596/2014 of transactions related to shares in FLSmidth made by persons discharging managerial responsibilities in FLSmidth and/or persons closely associated with them. See the transactions of Group CEO Mikko Keto in the attached PDF document.Contacts: Investor RelationsJannick Lindegaard Denholt, +45 21 69 66 57, jli@flsmidth.comTherese Möllevinge, +45 41 37 16 38, tmo@flsmidth.comMikkel Johansen, +45 23 30 29 50, mjoh@flsmidth.com Media RelationsRasmus Windfeld, +45 40 44 60 60, rwin@flsmidth.comAbout FLSmidthFLSmidth provides sustainable productivity to the global mining and cement industries. We deliver market-leading engineering, equipment and service solutions that enable our customers to improve performance, drive down costs and reduce...